Teladoc Inc (NYSE:TDOC) CFO Mark Hirschhorn sold 30,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $989,700.00. Following the completion of the sale, the chief financial officer now owns 5,203 shares in the company, valued at $171,646.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Mark Hirschhorn also recently made the following trade(s):
- On Monday, October 16th, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The shares were sold at an average price of $32.37, for a total value of $809,250.00.
- On Tuesday, October 17th, Mark Hirschhorn sold 35,000 shares of Teladoc stock. The shares were sold at an average price of $32.84, for a total value of $1,149,400.00.
- On Monday, October 2nd, Mark Hirschhorn sold 10,000 shares of Teladoc stock. The shares were sold at an average price of $34.04, for a total value of $340,400.00.
- On Friday, September 22nd, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The shares were sold at an average price of $31.93, for a total value of $798,250.00.
Teladoc Inc (NYSE TDOC) opened at $35.95 on Friday. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc Inc has a 1-year low of $15.65 and a 1-year high of $37.90.
Teladoc (NYSE:TDOC) last released its earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The firm had revenue of $68.70 million for the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The company’s quarterly revenue was up 112.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.33) EPS. sell-side analysts anticipate that Teladoc Inc will post -1.56 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. ETF Managers Group LLC acquired a new stake in shares of Teladoc during the 2nd quarter worth approximately $104,000. Bank of Montreal Can increased its position in Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after acquiring an additional 2,397 shares during the period. Pacad Investment Ltd. acquired a new stake in Teladoc in the 2nd quarter valued at approximately $135,000. Fred Alger Management Inc. acquired a new stake in Teladoc in the 2nd quarter valued at approximately $139,000. Finally, Legal & General Group Plc increased its position in Teladoc by 66.3% in the 1st quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock valued at $154,000 after acquiring an additional 2,446 shares during the period.
Several brokerages have commented on TDOC. Deutsche Bank began coverage on Teladoc in a research note on Friday, December 8th. They set a “buy” rating and a $39.00 price target for the company. KeyCorp restated a “buy” rating and set a $39.00 price target on shares of Teladoc in a research note on Monday, December 4th. CIBC restated an “outperform” rating and set a $45.00 price target (up from $40.00) on shares of Teladoc in a research note on Tuesday, November 21st. Oppenheimer upped their price target on Teladoc from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 21st. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $31.00 target price on shares of Teladoc in a research note on Monday, November 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $39.15.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/16/teladoc-inc-tdoc-cfo-sells-989700-00-in-stock.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.